Company profile: Salix Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of specialty pharmaceuticals focused on preventing and treating gastrointestinal disorders, licensing, developing, and marketing therapies including XIFAXAN for IBS-D and reducing overt hepatic encephalopathy recurrence; RELISTOR for opioid-induced constipation; TRULANCE for chronic idiopathic constipation and IBS-C; UCERIS for ulcerative colitis; MOVIPREP and PLENVU for colonoscopy bowel preparation.
Products and services
- TRULANCE (plecanatide): plecanatide-based therapy indicated for chronic idiopathic constipation and irritable bowel syndrome with constipation, delivering treatment specifically for persistent constipation in gastrointestinal disorders
- UCERIS (budesonide): extended-release budesonide therapy used for ulcerative colitis, offered as tablets and rectal foam to accommodate different administration forms for managing the condition
- XIFAXAN (rifaximin): antibiotic-class medication used to treat irritable bowel syndrome with diarrhea and to reduce the risk of overt hepatic encephalopathy recurrence
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Salix Pharmaceuticals
Plexxikon
HQ: United States
Website
- Description: Provider of small molecule pharmaceuticals focused on discovering and developing therapies for human diseases. Portfolio includes Zelboraf for BRAF V600E–mutant skin cancer, Turalio for tenosynovial giant cell tumor (TGCT), and personalized medicines. Pipeline candidates include PLX204 for diabetes, PLX4032 for melanoma and colorectal cancer, and PLX5568 kinase inhibitors for pain and polycystic kidney disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Plexxikon company profile →
Talecris
HQ: Spain
Website
- Description: Provider of plasma-derived protein therapies, produced and marketed by a biopharmaceutical company founded in 2004 and based in Barcelona, Spain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Talecris company profile →
Bristol Myers Squibb
HQ: United States
Website
- Description: Provider of pharmaceuticals, engaging in the discovery, development, licensing, manufacturing, marketing, distribution and sale of therapies, including cancer immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab); anticoagulant Eliquis (apixaban); oncology treatments Revlimid (lenalidomide) and Sprycel (dasatinib); and autoimmune therapy Orencia (abatacept).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bristol Myers Squibb company profile →
Arena Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development focused on cardiovascular, central nervous system, inflammatory, and metabolic diseases, including the development of lorcaserin hydrochloride, which has reported positive clinical trial data. Headquartered in San Diego, CA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arena Pharmaceuticals company profile →
CoGenesys
HQ: United States
Website
- Description: Provider of peptide- and protein-based medicine development for cancer, cardiovascular, metabolic, infectious, autoimmune, and CNS diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CoGenesys company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Salix Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Salix Pharmaceuticals
2.2 - Growth funds investing in similar companies to Salix Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Salix Pharmaceuticals
4.2 - Public trading comparable groups for Salix Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →